Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection

HIV Clinical Trials

Volumn 5, Issue 5, 2004, Pages 294-304

  Simpson, Kit N ^a,c   Luo, Michelle P ^b   Chumney, Elinor ^a   Sun, Eugene ^b   Brun, Scott ^b   Ashraf, Talat ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c Dept of Hlth Administration/Policy ^*  (United States)

Author keywords

Cost effectiveness; Lopinavir; Nelfinavir; Resistance

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; STAVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG USE; HEALTH CARE COST; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; T LYMPHOCYTE; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; ILLINOIS; MALE; MARKOV CHAINS; MIDDLE AGED; NELFINAVIR; PYRIMIDINONES; QUALITY OF LIFE; RITONAVIR; VIRAL LOAD;

EID: 9144267049     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/WT81-MEM4-5C4L-CHPK     Document Type: Article

References (24)

1. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346(26):2039-2046.
2. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4-year follow-up of study 720. AIDS. 2004;18(5):775-779.
3. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy Antivir Ther. 2002;7(3):165-174.
4. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
5. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189(1):51-60.
6. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22(3):216-224.
7. Price Probe Data Base 2002. www.FirstDataBank.com
8. Gold M, Siegel J, Russell L, et al., eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
9. Simpson K, Hatziandreu EJ, Andersson F, Shakespeare A, Oleksey I, Tosteson ANA. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4 counts less than 300/μL in 5 European countries. Pharmacoeconomics. 1994; 6:553-562.
10. Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997;12:54-66.
11. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Eng J Med. 2001;344(11):824-831.
12. Goldie SJ, Kaplan JE, Losina E, et al. Prophylaxis for human immunodeficiency virus-related Pneumocystis cariini pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med. 2002;162(8):921-928.
13. Ghani AC, de Wolf F, Ferguson NM, et al. Surrogate markers for disease progression in treated HIV infection. JAIDS. 2001;28(3):226-231.
14. Ghani AC, Henley WE, Donnelly CA, Mayer S, Andersen RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS. 2001;15(9):1133-1142.
15. Simpson KN, Voit EO, Goodman R, Chumney ECG. Estimating the social and economic benefits of pharmaceutical innovations: modeling clinical trial results in HIV-disease. Res Hum Capital Dev. 2001;(14):175-198.
16. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Defic Syndr. 2004; 36(5):1028-1033.
17. Andrulis D, Weslowski V, Hintz E, et al. Comparisons of hospital care for patients with AIDS and other HIV-related conditions. JAMA. 1992;267:2482-2486.
18. Bureau of Labor Statistics. Consumer Price Index, Medical Care. http://data.bls.gov/servlet/SurveyOutputServlet. Accessed April 17, 2002.
19. Dolan P. Modeling valuations for EuroQoL health states. Medical Care. 1998;35:1095-1108.
20. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, July 14, 2003. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). www.Guideline.gov
21. King M, Bernstein B, Cernohous P, et al. Impact of baseline CD4 cell count and viral load on durability of virologic response through 96 weeks for lopinavir/ritonavir and nelfinavir in a phase III clinical trial. Presented at: the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002. Poster number 470-M.
22. Richter A, Hauber B, Simpson K, Mauskopf JA, Yin D. A Monte Carlo simulation for modeling outcomes of AIDS treatment regimens. Pharmacoeconomics. 2002;20(4): 215-224.
23. Laupacis A, Feeny D, Detsky A, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. J Can Med Assoc. 1992;146:473-481.
24. Committee on the Public Financing and Delivery of HIV Care. Board on Health Promotion and Disease Prevention. Institute of Medicine. Public Financing of HIV/AIDS Care: Securing the Legacy of Ryan White Washington, DC: The National Academy Press; 2004:196.